We are analyzing https://link.springer.com/article/10.1007/s11523-016-0444-7.

Title:
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines | Targeted Oncology
Description:
Background Targeting of class I histone deacetylases (HDACs) exerts antineoplastic actions in various cancer types by modulation of transcription, upregulation of tumor suppressors, induction of cell cycle arrest, replication stress and promotion of apoptosis. Class I HDACs are often deregulated in urothelial cancer. 4SC-202, a novel oral benzamide type HDAC inhibitor (HDACi) specific for class I HDACs HDAC1, HDAC2 and HDAC3 and the histone demethylase LSD1, shows substantial anti-tumor activity in a broad range of cancer cell lines and xenograft tumor models. Aim The aim of this study was to investigate the therapeutic potential of 4SC-202 in urothelial carcinoma (UC) cell lines. Methods We determined dose response curves of 4SC-202 by MTT assay in seven UC cell lines with distinct HDAC1, HDAC2 and HDAC3 expression profiles. Cellular effects were further analyzed in VM-CUB1 and UM-UC-3 cells by colony forming assay, caspase-3/7 assay, flow cytometry, senescence assay, LDH release assay, and immunofluorescence staining. Response markers were followed by quantitative real-time PCR and western blotting. Treatment with the class I HDAC specific inhibitor SAHA (vorinostat) served as a general control. Results 4SC-202 significantly reduced proliferation of all epithelial and mesenchymal UC cell lines (IC50 0.15–0.51 μM), inhibited clonogenic growth and induced caspase activity. Flow cytometry revealed increased G2/M and subG1 fractions in VM-CUB1 and UM-UC-3 cells. Both effects were stronger than with SAHA treatment. Conclusion Specific pharmacological inhibition of class I HDACs by 4SC-202 impairs UC cell viability, inducing cell cycle disturbances and cell death. Combined inhibition of HDAC1, HDAC2 and HDAC3 seems to be a promising treatment strategy for UC.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

cells, cell, treatment, hdac, pubmed, article, fig, google, scholar, cancer, saha, cas, histone, vmcub, inhibitor, cycle, treated, umuc, control, urothelial, romidepsin, uccs, class, inhibition, analysis, lines, apoptosis, germany, hblak, death, performed, morphology, hdacs, effects, inhibitors, expression, carcinoma, hdaci, activity, viability, online, central, induction, assay, resource, acetylation, lsd, hek, dmso, necrosis,

Topics {✒️}

5-bromo-4-chloro-3-indolyl-beta-d-galacto-pyranoside extent double-strand breaks sa-β-gal positive cells quantitative real-time pcr article download pdf open access publication isotype-specific hdac inhibitor carrillo-de-santa-pau sa-β-gal staining pik3 kinase/akt signaling related subjects tata-box binding protein isotype-specific hdac inhibitors pan-nuclear dna damage β-gal staining solution 35 μg/ml n-epinephrine high-dose-intensity methotrexate late apoptotic/necrotic cells 1 mg/ml x-gal pan-hdac inhibitor control full size image pan-hdac inhibitor saha cell lines um-uc-3 cell line vm-cub1 50 μg/ml propidium iodide chromatin-mediated transcriptional response metastatic urothelial carcinoma renal cell carcinoma q-vd-oph inhibitor treated vm-cub1 colony forming assay necrotic cell death western blot analysis epidermal growth factor ca2+/fcs differentiation protocol cell cycle progression versus interferon-alpha privacy choices/manage cookies hepatocellular carcinoma cells class i-specific hdaci long-term survival results oral hdac inhibitor article pinkerneil vm-cub1 cells treated vm-cub1 treated cells advanced urothelial cancer cancer cell lines cell cycle arrest anti-cancer drugs original author

Questions {❓}

HDAC family: what are the cancer relevant targets?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
         description:Targeting of class I histone deacetylases (HDACs) exerts antineoplastic actions in various cancer types by modulation of transcription, upregulation of tumor suppressors, induction of cell cycle arrest, replication stress and promotion of apoptosis. Class I HDACs are often deregulated in urothelial cancer. 4SC-202, a novel oral benzamide type HDAC inhibitor (HDACi) specific for class I HDACs HDAC1, HDAC2 and HDAC3 and the histone demethylase LSD1, shows substantial anti-tumor activity in a broad range of cancer cell lines and xenograft tumor models. The aim of this study was to investigate the therapeutic potential of 4SC-202 in urothelial carcinoma (UC) cell lines. We determined dose response curves of 4SC-202 by MTT assay in seven UC cell lines with distinct HDAC1, HDAC2 and HDAC3 expression profiles. Cellular effects were further analyzed in VM-CUB1 and UM-UC-3 cells by colony forming assay, caspase-3/7 assay, flow cytometry, senescence assay, LDH release assay, and immunofluorescence staining. Response markers were followed by quantitative real-time PCR and western blotting. Treatment with the class I HDAC specific inhibitor SAHA (vorinostat) served as a general control. 4SC-202 significantly reduced proliferation of all epithelial and mesenchymal UC cell lines (IC50 0.15–0.51 μM), inhibited clonogenic growth and induced caspase activity. Flow cytometry revealed increased G2/M and subG1 fractions in VM-CUB1 and UM-UC-3 cells. Both effects were stronger than with SAHA treatment. Specific pharmacological inhibition of class I HDACs by 4SC-202 impairs UC cell viability, inducing cell cycle disturbances and cell death. Combined inhibition of HDAC1, HDAC2 and HDAC3 seems to be a promising treatment strategy for UC.
         datePublished:2016-06-02T00:00:00Z
         dateModified:2016-06-02T00:00:00Z
         pageStart:783
         pageEnd:798
         sameAs:https://doi.org/10.1007/s11523-016-0444-7
         keywords:
            HDAC Inhibitor
            Urothelial Carcinoma
            SAHA
            Vorinostat
            Necrotic Cell Death
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig8_HTML.gif
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Maria Pinkerneil
               affiliation:
                     name:Heinrich-Heine-University
                     address:
                        name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michèle J. Hoffmann
               affiliation:
                     name:Heinrich-Heine-University
                     address:
                        name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hella Kohlhof
               affiliation:
                     name:4SC AG
                     address:
                        name:4SC AG, Martinsried, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wolfgang A. Schulz
               affiliation:
                     name:Heinrich-Heine-University
                     address:
                        name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Günter Niegisch
               affiliation:
                     name:Heinrich-Heine-University
                     address:
                        name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
      description:Targeting of class I histone deacetylases (HDACs) exerts antineoplastic actions in various cancer types by modulation of transcription, upregulation of tumor suppressors, induction of cell cycle arrest, replication stress and promotion of apoptosis. Class I HDACs are often deregulated in urothelial cancer. 4SC-202, a novel oral benzamide type HDAC inhibitor (HDACi) specific for class I HDACs HDAC1, HDAC2 and HDAC3 and the histone demethylase LSD1, shows substantial anti-tumor activity in a broad range of cancer cell lines and xenograft tumor models. The aim of this study was to investigate the therapeutic potential of 4SC-202 in urothelial carcinoma (UC) cell lines. We determined dose response curves of 4SC-202 by MTT assay in seven UC cell lines with distinct HDAC1, HDAC2 and HDAC3 expression profiles. Cellular effects were further analyzed in VM-CUB1 and UM-UC-3 cells by colony forming assay, caspase-3/7 assay, flow cytometry, senescence assay, LDH release assay, and immunofluorescence staining. Response markers were followed by quantitative real-time PCR and western blotting. Treatment with the class I HDAC specific inhibitor SAHA (vorinostat) served as a general control. 4SC-202 significantly reduced proliferation of all epithelial and mesenchymal UC cell lines (IC50 0.15–0.51 μM), inhibited clonogenic growth and induced caspase activity. Flow cytometry revealed increased G2/M and subG1 fractions in VM-CUB1 and UM-UC-3 cells. Both effects were stronger than with SAHA treatment. Specific pharmacological inhibition of class I HDACs by 4SC-202 impairs UC cell viability, inducing cell cycle disturbances and cell death. Combined inhibition of HDAC1, HDAC2 and HDAC3 seems to be a promising treatment strategy for UC.
      datePublished:2016-06-02T00:00:00Z
      dateModified:2016-06-02T00:00:00Z
      pageStart:783
      pageEnd:798
      sameAs:https://doi.org/10.1007/s11523-016-0444-7
      keywords:
         HDAC Inhibitor
         Urothelial Carcinoma
         SAHA
         Vorinostat
         Necrotic Cell Death
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-016-0444-7/MediaObjects/11523_2016_444_Fig8_HTML.gif
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Maria Pinkerneil
            affiliation:
                  name:Heinrich-Heine-University
                  address:
                     name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michèle J. Hoffmann
            affiliation:
                  name:Heinrich-Heine-University
                  address:
                     name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hella Kohlhof
            affiliation:
                  name:4SC AG
                  address:
                     name:4SC AG, Martinsried, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wolfgang A. Schulz
            affiliation:
                  name:Heinrich-Heine-University
                  address:
                     name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Günter Niegisch
            affiliation:
                  name:Heinrich-Heine-University
                  address:
                     name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:11
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Heinrich-Heine-University
      address:
         name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
         type:PostalAddress
      name:Heinrich-Heine-University
      address:
         name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
         type:PostalAddress
      name:4SC AG
      address:
         name:4SC AG, Martinsried, Germany
         type:PostalAddress
      name:Heinrich-Heine-University
      address:
         name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
         type:PostalAddress
      name:Heinrich-Heine-University
      address:
         name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Maria Pinkerneil
      affiliation:
            name:Heinrich-Heine-University
            address:
               name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
               type:PostalAddress
            type:Organization
      name:Michèle J. Hoffmann
      affiliation:
            name:Heinrich-Heine-University
            address:
               name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
               type:PostalAddress
            type:Organization
      name:Hella Kohlhof
      affiliation:
            name:4SC AG
            address:
               name:4SC AG, Martinsried, Germany
               type:PostalAddress
            type:Organization
      name:Wolfgang A. Schulz
      affiliation:
            name:Heinrich-Heine-University
            address:
               name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
               type:PostalAddress
            type:Organization
      name:Günter Niegisch
      affiliation:
            name:Heinrich-Heine-University
            address:
               name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
      name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
      name:4SC AG, Martinsried, Germany
      name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany
      name:Department of Urology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany

External Links {🔗}(236)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.19s.

LINK . SPRINGER . COM {}